Lantern Pharma's Starlight Therapeutics Receives FDA Clearance Its IND For Phase Ib/2a Glioblastoma Multiforme Trial
Benzinga Newsdesk 1 year ago
BiotechNewsFDAGeneral
Novel combination therapy with STAR-001 targets the most aggressive and deadliest forms of brain cancer at first progressionGBM represents an annual market opportunity of $3 to $5 billion USD with an accelerating number
- Novel combination therapy with STAR-001 targets the most aggressive and deadliest forms of brain cancer at first progression
- GBM represents an annual market opportunity of $3 to $5 billion USD with an accelerating number of cases globally
- Lantern Pharma has previously received both FDA Orphan and Fast Track Designations in GBM